[Federal Register Volume 82, Number 183 (Friday, September 22, 2017)]
[Notices]
[Pages 44428-44429]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20232]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
[email protected]. Licensing

[[Page 44429]]

information and copies of the U.S. patent applications listed below may 
be obtained by communicating with the indicated licensing contact at 
the Technology Transfer and Intellectual Property Office (TTIPO), 5601 
Fishers Lane, Suite 6D, MSC 9804, Rockville, MD 20892, tel: 301-496-
2644, fax: 240-627-3117. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Research Material: A Potent, Broadly-Neutralizing, Anti-HIV Antibody 
(35O22) That Binds a Novel Epitope

    Description of Technology: Millions of people are infected with 
HIV-1 worldwide. In the U.S., there are about 30,000 new cases of HIV 
infection reported annually. Researchers at NIAID are actively 
investigating broadly neutralizing anti-HIV-1 antibodies which can be 
used as therapeutics or prophylactics for HIV infection.
    NIAID and Scripps researchers have discovered a potent anti-HIV 
antibody (35O22) that binds a novel HIV epitope. This antibody 
neutralizes at least 80% of HIV isolates tested so far. The unique 
binding of 35O22 makes it an attractive candidate to combine with other 
HIV antibodies or antivirals in treating or preventing HIV infection.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 HIV-1 therapeutics
 HIV-1 prophylactics

    Competitive Advantages:

 Unique epitope
 Broad neutralization of HIV isolates

    Development Stage: Pre-Clinical.
    Inventors: Mark Connors, John Mascola, Peter Kwong, Tongqing Zhou, 
Jinghe Huang, Byong Ha Kang, all of NIAID, NIH; Andrew Ward, Scripps 
Research Institute.
    Publications: Huang, J et al., Broad and potent HIV-1 
neutralization by a human antibody that binds the gp41-gp120 interface. 
Nature 515, 138-142.
    Intellectual Property: Not applicable.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further develop 35O22 in combination with 
other NIAID antibodies. For collaboration opportunities, please contact 
Chris Kornak, 240-627-3705, [email protected].

    Dated: September 12, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-20232 Filed 9-21-17; 8:45 am]
 BILLING CODE 4140-01-P